As per the company’s Restated H1 2025 Financials, its continuing business delivered CORE EBITDA of CHF 922 million, representing a margin of 30.4%
Bolstering neuroscience push with late-stage Tourette therapy
CDMO strengthens global quality framework through digital transformation, AI-enabled investigations, workforce development and continuous audit readiness
Acquisition of Mumbai-based pharmaceutical, nutraceutical and cosmeceutical company expected to be completed by July 2026
The sale is part of a broader strategy to streamline its asset footprint and concentrate investment on core growth areas
The collaboration is focused on overcoming a major limitation in existing cancer drugs
Upon completion of the merger, Assertio will become a wholly owned subsidiary of Zydus Lifesciences and will be delisted from the Nasdaq
CEO Stéphane Bancel framed the changes as essential to scaling the business
The expansion adds 100 m³ of reactor capacity, significantly strengthening Siegfried’s position among the world’s leading CDMOs for small-molecule drug substances
Secures high-stakes glaucoma drug in up to $2.45b bet on eye care pipeline
Generic launch targets a US$19 million market in United States, strengthening Glenmark’s institutional and injectable product portfolio in North America
Leading experts from AIIMS Kalyani, Syngene, Veeda Lifesciences, Lambda Therapeutic, DNDi, JSS Medical, KIHT, InoRx, ISCR and SIRO Clintech to discuss India’s readiness as preferred clinical research destination
Market grows 12.1%; volume contribution improves as 9 out of 10 key therapies post double-digit growth
The FDA nod marks a step forward in precision oncology, linking molecular diagnostics more tightly to therapy selection for advanced prostate cancer
New facility will open by October 2026 and house 500 process development specialists
Dr Reddy’s has partnered with MSN Laboratories Private Limited on the product, with Dr Reddy’s holding exclusive US marketing rights while MSN leads development and manufacturing
The new facility aims to accelerate formulation science and application-led research across pharma, biopharma, nutraceuticals, personal care, and home care segments
New Shoolagiri plant strengthens Maiva’s global CDMO capabilities with advanced isolator technology, flexible production lines, and expanded capacity for complex injectable therapies
Exclusive licensing agreement combines Lonza’s dual-payload ADC technology with Antharis’ antibody engineering expertise
Samelisant will be the centerpiece of Suven’s scientific presence
Subscribe To Our Newsletter & Stay Updated
